Article

Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder

Alice Fiddian-Green 1,*, Aline Gubrium 2, Calla Harrington 2 and Elizabeth A. Evans 2

1 School of Nursing and Health Professions, University of San Francisco, San Francisco, CA 94117, USA
2 Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA; agubrium@schoolph.umass.edu (A.G.); callaharring@umass.edu (C.H.); eaevans@umass.edu (E.A.E.)

* Correspondence: afiddiangreen@usfca.edu

Abstract: Opioid-related fatalities increased exponentially during the COVID-19 pandemic and show little sign of abating. Despite decades of scientific evidence that sustained engagement with medications for opioid use disorders (MOUD) yields positive psychosocial outcomes, less than 30% of people with OUD engage in MOUD. Treatment rates are lowest for women. The aim of this project was to identify women-specific barriers and facilitators to treatment engagement, drawing from the lived experience of women in treatment. Data are provided from a parent study that used a community-partnered participatory research approach to adapt an evidence-based digital storytelling intervention for supporting continued MOUD treatment engagement. The parent study collected qualitative data between August and December 2018 from 20 women in Western Massachusetts who had received MOUD for at least 90 days. Using constructivist grounded theory, we identified major themes and selected illustrative quotations. Key barriers identified in this project include: (1) MOUD-specific discrimination encountered via social media, and in workplace and treatment/recovery settings; and (2) fear, perceptions, and experiences with MOUD, including mental health medication synergies, internalization of MOUD-related stigma, expectations of treatment duration, and opioid-specific mistrust of providers. Women identified two key facilitators to MOUD engagement: (1) feeling “safe” within treatment settings and (2) online communities as a source of positive reinforcement. We conclude with women-specific recommendations for research and interventions to improve MOUD engagement and provide human-centered care for this historically marginalized population.

Keywords: women and opioid use disorder; qualitative methods; medications for opioid use disorder; substance use treatment; stigma and substance use

1. Introduction

Opioid use in the U.S. has resulted in unparalleled rates of accidental injury, infectious disease (e.g., HIV, Hepatitis C), and premature death [1]. Opioid-related fatalities increased exponentially during the COVID-19 pandemic and show little sign of abating [2]. Some factors influencing opioid fatalities include social isolation; increased mental health issues; reduced access to treatment and services; and stress related to economic, social, and other factors. Prior to COVID-19, concerns specific to women were increasing rates of heroin use, slower decreases in rates of prescription opioid misuse [3], and increasing deaths associated with synthetic opioids and heroin [4]. Women with OUD currently remain a growing population of concern [5–7].

Sustained engagement with medications for opioid use disorder (MOUD) (e.g., buprenorphine, methadone, naltrexone) results in reduced mortality [8], lowered opioid use [9], fewer infectious disease risks [10], reduced engagement with the criminal justice system, and other positive outcomes [11]. The COVID-19 pandemic prompted innovations to reduce treatment barriers. For MOUD, this included relaxing regulations...
regarding take-home doses of methadone, expanding access to telemedicine, and allowing buprenorphine to be prescribed via telemedicine appointments [12,13]. These innovations show great promise for expanded access to treatment for people with OUD. However, we know the vast majority of people with OUD still do not access treatment [1]. According to 2019 estimates, less than 30% of individuals needing OUD treatment received MOUD [14]. Of those who do enter care, few remain engaged with MOUD long enough to achieve lasting recovery [15]; treatment rates are lower for women versus men [16,17]. Closing this treatment gap is paramount.

Factors that contribute to low rates of treatment engagement among women with OUD include high rates of trauma and sexual exploitation [8], mental health comorbidities [18,19], chronic pain [8,19,20], socioeconomic vulnerability, and housing insecurity [21,22]. Furthermore, women with substance use disorders face harsh stigma related to social expectations around maternal health and caregiving roles [23–25]; fears related to loss of child custody are substantial [26]. Finally, compared to men, women experience more heightened feelings of OUD-related shame and other internalized self-depreciating thoughts [8,27,28], resulting in fractured relationships [29] that leave women with little family and social support to remain engaged with treatment [18].

Prior research on women and substance use points to important treatment facilitators. These include trauma-informed and gender-specific treatment programs [16,26,30], positive therapeutic alliances [24], and positive social support [18,31]. Despite these insights into the women-specific causes and outcomes of substance use treatment engagement, we still know relatively little about the social and contextual factors that influence why or how women who do access MOUD remain engaged with it over time [24,32]. This article explores this knowledge gap, focusing on women-reported barriers, as well as facilitators, to MOUD engagement. Drawing from qualitative findings, we share critical context on the social and structural factors that influence engagement with the medical system among this historically marginalized population.

2. Methods

2.1. Study Design and Data Collection

Data presented are a subset from an exploratory sequential mixed methods [33] study that used a community-partnered participatory research (CPPR) approach [34] to adapt an evidence-based digital storytelling intervention [29,35] for supporting continued MOUD treatment engagement. The parent study consisted of three phases: relationship building, exploratory data collection, and patient workgroup sessions (Figure 1). Data in this manuscript draw from qualitative findings related to treatment engagement that surfaced during group and individual conversations with patients regarding adaptability and feasibility of a digital storytelling intervention during phase two of the project. Qualitative methods are best suited to generate novel findings that prompt innovations [36], of particular value when conducting research with a stigmatized population and topic (i.e., women and M/OUD).

To elicit information for intervention development, qualitative data were collected from 20 women enrolled in two outpatient Opioid Treatment Programs (OTP) located in Western Massachusetts and operated by one of the region’s largest behavioral health services providers. Both facilities are licensed to administer three FDA-approved MOUD maintenance therapies: methadone, buprenorphine, and naltrexone. Inclusion criteria included: (1) self-identified adult woman, (2) who has received MOUD from a participating OTP for at least 90 days, and (3) has no cognitive impairment that would disallow informed consent. Twenty women were recruited via flyers distributed in the OTPs, referrals from clinical staff, and participant word of mouth. Research staff conducted in-depth interviews; participants also completed brief anonymized surveys on demographics and questionnaires related to substance use history and treatment factors (Appendix A). Participants were compensated with USD25 gift cards. Interviews were digitally recorded, professionally transcribed, de-identified, and reviewed for accuracy. All procedures were approved by
the OTP’s affiliated Institutional Review Board, and each participant provided written informed consent.

**Figure 1.** CPPR Project Phases: Adaptation of Digital Storytelling Intervention to Enhance Engagement for Women Enrolled in Opioid Treatment Programs (OTP). * Source of data presented in this manuscript.

Data were collected from August to December 2018. In-depth group interviews were conducted with 20 patients and facilitated by the first and last author. The majority of sessions were attended by an average of 2–4 participants; two sessions were conducted with one individual each. Interview sessions lasted 1.5 to 2 h, and were conducted in private rooms at participating OTPs. Each interview opened with a grand tour prompt on barriers and facilitators to continued MOUD engagement. Remaining interview questions elicited information on attitudes, beliefs, and perceived utility of using a digital storytelling intervention to increase MOUD engagement; expected intervention outcomes; and potential challenges/solutions associated with intervention pilot-testing and further development (Appendix B). In this paper, we summarize qualitative findings from the grand tour prompt on barriers and facilitators.

**2.2. Data Analysis**

Data analysis was guided by constructivist grounded theory [37], an iterative approach that involves simultaneous data collection and analysis; inductive code development; using “constant comparison” to compare and contrast categories; memo-writing to identify and define thematic categories and any connections between them, as well as identifying gaps; and sampling for construction of meaning, not for generalizability [37–39]. Our analytic strategy was to examine narrative content and context [40–42]. Narrative content analysis focused on women-specific paradigms of OUD found in the data at both the individual and group level. Contextual analysis focused on the perceptions and structural circumstances (e.g., historical, political, economic) that shape identity and experience [41].

Informed by standard qualitative data analysis procedures [33,43,44], the first and last authors independently reviewed transcripts and conducted open-coding, using theoretical memo-writing to identify and develop evolving themes. Next, each researcher composed a list of thematic codes derived directly from the data. Then, we reviewed and compared emerging themes collectively and iteratively to reach thematic saturation and

---

**Phase 1**

- **Relationship Building**
  - Identification of community partner
  - Collaboration, communication, project planning

**Phase 2**

- **Exploratory Data Collection**
  - *Group interview sessions with patients (n=20)
  - Two (2) focus groups with staff
  - 90-120 minutes in duration

**Phase 3**

- **Patient Workgroup Sessions**
  - Six (6) Patient workgroup sessions
  - Member checking and intervention development
  - 60-90 minutes in duration

---
determine final themes [33,43]. During data analysis, we assessed the selected quotes to ensure they represented the diversity of participants and perspectives. Member checking during patient workgroup sessions in phase three of the project (Figure 1) further ensured trustworthiness of our thematic findings. We used reflexivity to balance interpretive authority and participants’ experiences and perceptions [33,44]; this included being conscious of power dynamics associated with conducting research with patients in clinical sites. To this last point, participants stated their eagerness to share MOUD treatment experiences with research staff that they would not share with clinical staff, expressing greater comfort in discussing these topics with individuals unaffiliated with the clinic and who do not provide care.

3. Results

Twenty women being treated for OUD participated in the study (Table 1). Participants self-identified as white non-Hispanic (65%), Latina (30%), and African-American (5%); the mean age was 36.6 years. Sixty-five percent reported some college or a bachelor’s degree. Only 20% of the sample were employed full-time, and 80% had an average annual income of <$USD20,000. Mean duration of opioid use was 4.6 years; average duration of current MOUD treatment was 2.8 years. Below, we summarize key thematic results (Table 2), highlighting barriers and facilitators to MOUD engagement. Barriers include two themes: (1) community-level social stigma and (2) fear, perceptions, and experiences with MOUD. Facilitators to MOUD engagement include (1) a sense of safety within treatment settings and (2) social media and online communities as a source of positive social support.

Table 1. Participant characteristics.

| Women (n = 20) |          |
|---------------|----------|
| Age (mean ± SD) | 36.6 ± 9.5 years |
| **Race/ethnicity** |          |
| White, Non-Hispanic | 65% (13) |
| Black, Non-Hispanic | 5% (1) |
| Hispanic or Latina/x | 30% (6) |
| **Educational attainment** |          |
| <High school/HiSET | 5% (1) |
| High school/HiSET/Vocational | 30% (6) |
| Some college/Associate’s degree | 60% (12) |
| Bachelor’s degree | 5% (1) |
| **Employment status** |          |
| Employed full-time | 20% (4) |
| Employed part-time | 15% (3) |
| Laid off/Unemployed | 30% (6) |
| Disabled and not working | 25% (5) |
| Retired and not working | 10% (2) |
| **Household income in last 12 months** |          |
| <$10,000 | 45% (9) |
| $10,001–$20,000 | 35% (7) |
| $20,001–$40,000 | 15% (3) |
| $40,001–$75,000 | 5% (1) |
| **Opioid use (mean± SD)** |          |
| Age at 1st initiation of opioid use | 26.6 ± 7.1 years |
| Average duration of opioid use | 4.6 ± 5.0 years |
| **Current MOUD treatment** |          |
| Age at 1st first treatment (mean ± SD) | 31.3 ± 11.1 years |
| Current MOUD treatment duration (mean ± SD) | 2.8 ± 2.4 years |
Table 2. Key thematic findings, barriers and facilitators to MOUD engagement.

| Barriers                                      | Facilitators                                |
|----------------------------------------------|---------------------------------------------|
| 1. Interpersonal and Community-Based Social Stigma | 1. Sense of safety in treatment settings    |
| 1.1 Family and social networks               | 2. Support from online communities          |
| 1.2 Workplace settings                       |                                             |
| 1.3 Social media                             |                                             |
| 1.4 Hierarchies within the treatment and recovery community |                                             |
| 2. Fear, Perceptions, and Experiences with MOUD Pharmacotherapies |                                             |
| 2.1 Fear of side effects and medication synergies |                                             |
| 2.2 Internalized MOUD-Related Stigma         |                                             |
| 2.3 Expectations of treatment duration       |                                             |
| 2.4 Opioid-specific provider mistrust        |                                             |

3.1. Community-Level Social Stigma

Women in our study commonly reported feeling unable to escape the identity of “drug user loser” a stigma that “doesn’t go away until the day you die—you’re always going to be ‘that junkie.’” Despite positive treatment outcomes (e.g., abstaining from illicit substance use, employment, and maintaining child custody), women identified a persistent social discourse wherein successful engagement with MOUD did not guarantee an escape from gendered negative associations related to active substance use such as sex work and child neglect. Women reported that the social consequences of being “outed” (i.e., discovered) as a MOUD patient posed substantial barriers to continued MOUD engagement in two ways. First, MOUD directly links women to active substance use and second, MOUD is widely perceived to be an illegitimate form of treatment. Participants shared how MOUD-related community-level social stigma operates within three spaces: workplace settings, social media, and hierarchies within treatment and recovery settings.

3.1.1. Workplace Settings

Workplace environments were identified as sites of discrimination, which may explain one way that being “outed” as a MOUD patient can negatively impact treatment engagement. A considerable anxiety was the potential of employers learning of participants’ MOUD status. In one group interview session, the general consensus was that women alternatively hid, or actively lied about, how MOUD treatment policies impacted job-related behaviors. For example, women agreed they would be more likely to tell an employer their child was sick, rather than explaining that lateness was treatment related (e.g., mandatory counseling or long lines). One participant who had not experienced workplace discrimination firmly believed that if she shared her MOUD status she would not be trusted by superiors or peers. She worried that if the cash register was “short” she would be blamed for stealing the money because of assumptions linking her past illicit substance use to criminal behavior.

Women in multiple interview sessions discussed their reluctance to reveal their MOUD status in the workplace due to fear of inter-employee discrimination. As one example, a woman in treatment who worked in a hospital told her peers she sometimes wants to shout “I am one of them!” when coworkers speak disparagingly about ‘these people, nothing but drug addicts’ who enter the hospital. A second woman reported driving hours to receive treatment outside her small, rural town, because at work she hears coworkers “talking all this nasty stuff” about “drug addicts.” A third participant recounted a coworker who was open about his MOUD treatment. Although he did not experience negative repercussions related to his employment status, “everyone judged him behind his back.” As a result, that participant was adamant she would “never” tell anyone at work about her MOUD status.
3.1.2. Social Media

In one group interview, women identified social media as a site of “constant debate”, between whether OUD is a “disease or … a choice” and a space where the validity of MOUD as a legitimate medical treatment is publicly questioned. For example, the women shared examples of memes they perceived as derogatory. The caption of one image described read: “when you’re on Suboxone you’re not really clean—it’s like the government is legal drug-dealing.” Over “400 comments” were posted in response, predominantly reinforcing this messaging. Another meme was “laughing about ‘when your girl says she’s clean’ and then it shows a picture of her walking into a methadone clinic or something,” each perpetuating notions equating MOUD to active substance use. Other examples cited were memes or posts such as “people have to pay for Epi pens but Narcan® is free?” and “a person chooses to [mess] up their life and they get to get saved?”

3.1.3. Hierarchies within Treatment and Recovery Settings

Across all interview sessions women shared experiences of between-women social hierarchies within treatment settings. These hierarchies position women against each other, resulting in discrimination levied from “drug addict to drug addict.” This internalized stigma manifests as a hierarchical value system within treatment and recovery spaces, which can function as an impediment to peer support and deter women from treatment engagement. Women discussed encountering such recovery hierarchies within Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) chapters, some of which did not consider MOUD a legitimate component of recovery. This experience was reportedly pronounced for pregnant women and mothers, especially those living in small, rural communities. In one example, a participant—a mother—attended AA meetings in her town, but introduced herself as an alcoholic to avoid judgement and receive the peer support she identified as crucial to her MOUD engagement.

Although not self-identified as such, women appeared to internalize broader social stigma regarding women with OUD. Between women with OUD, recovery hierarchies were further entrenched by a predominating social stigma that associates women with OUD to sex work and incarceration. According to participants in a group interview session, when people “hear you’re an addict, especially heroin or cocaine, they’re like ‘… she’s a prostitute and she’s dirty.’” Participants acknowledged that fear of these associations can minimize transparency about substance use history. At the same time, participants—who were in treatment—appeared to internalize this messaging and turn that same judgement towards women actively using. For example, during that group interview participants spoke disparagingly about women engaging in sex work in exchange for drugs, referring to them as “nasty.” In that same discussion, participants in the group expressed strong opposition to providing MOUD to incarcerated individuals referring to such programs as “outrageous” and incarcerated people as not “deserving” of MOUD. Participant critiques of such programs—“you’re in jail, why are our tax dollars going to that?!” and “there should be no drugs in jail”—equate MOUD to active substance use, a contradiction that appeared to go unnoticed by participants.

3.2. Fears, Perceptions, and Experiences with MOUD Pharmacotherapies

This project elicited three main concerns with regard to MOUD: (1) fear of side effects and medication synergies, (2) unrealistic expectations of treatment duration, and (3) opioid-specific provider mistrust.

3.2.1. Fear of Side Effects and Medication Synergies

Women identified various medication side effects and synergies, perceived or otherwise, which may negatively impact MOUD engagement. All women interviewed in the project were being treated with methadone. Two sisters who participated in one interview session reported their “ex-stepmother” was a registered nurse who believed methadone is “liquid fire that kills you from the inside out.” When asked to identify side effects of
methadone complaints expressed by three different women were that “it eats at your bones,” “your teeth are all going to fall out,” and it makes women “fat.” A participant with extensive tooth decay worried aloud that “if this is happening to my teeth, I can’t imagine what’s going on with my bones.” The other women in her group interview nodded in agreement, adding that MOUD side-effects related to physical attributes such as weight gain and visible tooth decay contributed to low self-esteem. Lastly, one woman receiving pharmaceutical treatment for both OUD and mental health comorbidities raised concerns related to perceived synergies between mental health pharmacotherapies and MOUD. Women in her group agreed that common concerns regarding medication synergies included “nodding off” (i.e., increased fatigue) and dampening of MOUD efficacy.

3.2.2. Expectations of Treatment Duration

When discussing patient–provider communication and education during one group interview session, participants identified frustrations related to unrealistic expectations of treatment duration. Upon enrollment, patients are reportedly told: “we’re going to get you on a steady dose and wean you off within six months.” Yet the average treatment duration among participants was nearly three years. Further, the prospect of long-term engagement with MOUD was noted to be a source of considerable discouragement. As one participant illustrated: “Every story ends up being somebody getting off [MOUD] and being great—for a very short period of time. I’ve never heard of it, actually. Of someone coming off of [MOUD] ever. I’ve never.”

Compounding unrealistic expectations of treatment duration was a purported lack of information for women to make an informed choice between MOUD pharmacotherapies (e.g., methadone, buprenorphine, or naltrexone). In a group interview discussion about medication, women interested in switching to buprenorphine expressed frustrations about feeling “stuck” on methadone treatment, expressing irritation with reported difficulties in tapering methadone doses. For one participant “Honestly, if I had the money, I would do pills for three months and then go to detox for pills . . . It’s five times worse to come off methadone.” Other participants in the group felt vexed that it can take “thirty to ninety days to withdraw from methadone . . . That is months of being sick. That is insane. If I had known that, I would never have gotten on it. Ever.”

3.2.3. Opioid-Specific Provider Mistrust

A barrier to MOUD engagement identified in this project was increased mistrust of providers due to the iatrogenic impact of provider prescribing practices on the opioid crisis. In one group interview participant comments centering blame on physicians, for example, “I would say at least 50% of us, it (prescription opiate) was given to us by a doctor and that’s how it started,” were common. One woman additionally expressed a mistrust of providers related to conspiracy theories centered on unethical relationships between providers and the pharmaceutical industry. In agreeing with her, another woman in the group stated she was hesitant to believe that MOUD was the best treatment option “because on some end [the doctor] is also a pusher, a dealer. I’m coming here to get my fix and they’re going to benefit [by getting] X amount of dollars for each person that comes here.”

3.3. Facilitators to Treatment Engagement

In addition to the above findings on barriers to MOUD treatment engagement, we additionally report on women-identified facilitators of MOUD treatment engagement. Facilitators identified included feeling a sense of safety within treatment settings, and online communities as a source of support and encouragement.

3.3.1. Sense of Safety within Treatment Settings

Feeling safe within treatment settings was cited as paramount for participants to remain engaged with MOUD treatment protocols, especially for those with self-identified trauma histories. Simple acts of kindness from clinicians and staff fostered a sense of safety.
and loyalty to a particular treatment setting. For this highly stigmatized population, having someone remember their name or share a smile left participants feeling “shocked” yet valued. Examples of positive provider encouragement included “doctors where as soon as they found out I was on [MOUD], they give me high fives and they’re like, that’s amazing!” and a clinician who told one participant “I’ve learn[ed] a lot of things from you...I learn from you, you learn from me. We learn from each other.”

The integration of peer workers (i.e., “recovery coaches”) into the treatment setting was identified as critical for fostering a sense of safety. Peer workers were described as being an important source of empathetic and relatable support grounded in shared lived experiences. During one group interview, women recounted feeling “frustrated” when assigned to counselors who compared heroin to “sugar or soda” or suggested going “for a jog around the block” as an alternative to “using.” During this session women resoundingly reported wanting to interact with a peer worker—someone that “‘shares the struggle,’ because [i]t’s not as easy as people think it is.” On-site peer workers reportedly represent a form of “hope,” in part due to their sustained recovery that is a requisite of the job. Women reported aspiring towards becoming certified as peer workers as a meaningful way to “give back” to others once they achieved treatment stability.

3.3.2. Support from Online Communities

Despite being a reported source of discrimination, participants simultaneously reported positive social connection and support from online communities of people enrolled in MOUD treatment. In one group interview, one woman shared that of her 250 Facebook friends, the majority were “people in recovery.” A second woman described a “before-and-after” post where people were sharing side-by-side images of themselves in active addiction versus MOUD treatment. Comments on those images were largely supportive, “like, ‘how amazing, you’re doing so great... you look 10 times better!’” The value of these groups was in feeling less alone—knowing “you’re not the only one [enrolled in MOUD treatment].”

4. Discussion

4.1. Discussion and Implications for Practice

Our findings on community-level sources of social stigma illustrate moral models of addiction that remain entrenched in society. Women universally shared that a barrier to MOUD engagement was their inability to escape their past identity as substance user, regardless of gains made through treatment. Furthermore, MOUD-based stigma highlights persistent notions of MOUD as a form of active substance use, despite medical guidelines to the contrary [45]. In keeping with the literature, the stigma experienced by women was largely due to gendered associations between OUD, sex work, and parental neglect [23,46]. Women expressed substantial fears associated with consequences of being “outed” as a person in MOUD treatment, and their intent to “pass” as “normal” by maintaining some level of secrecy.

Our findings on the existence of hierarchies within treatment settings and recovery communities that can be discriminatory align with the existing, yet scant, literature [47]. Hierarchies can function as an impediment to peer support and deter women from treatment engagement. Considering the range of hierarchies [48,49] that may be present between women in clinical- and community-based treatment settings may offer important direction for future iterations of women-specific MOUD treatment programming. To be trauma-informed [50], women-specific treatment programs should address relational factors that impact women [51–53], and incorporate guidelines for skill-building to improve communication so these groups can be sources of positive social support.

Employment can be an important contributor to sustained recovery and MOUD engagement. Employment is particularly critical for women with OUD, who experience higher rates of socioeconomic insecurity compared to men [53–55]. Additionally, employment can be tied to custody requirements for mothers with OUD [56]. Our results indicated
workplace environments as sources of discrimination. This finding coincides with emerging studies [57] and suggests a need for anti-stigma interventions and education outreach in the workplace, as well as potential collaborations between treatment and workplace settings (e.g., transportation access and shift flexibility). More research is needed to understand how workplace MOUD-based discrimination may impact men and women differently.

An important discovery was inter-employee workplace stigma in medical settings, which may reinforce fears associated with provider stigma [58] and deter treatment engagement. As such, it may be useful to consider people with OUD as a distinct cultural group, i.e., a group that exposes individuals to different forms of discrimination that, in turn, contributes to health inequities. Following this idea, concepts from cultural humility [59,60] and structural competency [61] may offer strategies to address these barriers to MOUD engagement.

Our findings on social media as a site of community-level discrimination are valuable, given its omnipresence in today’s society. Suicide prevention and other public health efforts have recognized that hopeless media depictions of high-risk individuals may increase suicide attempts [62]. Similarly, condemning people seeking MOUD on social media may deter those considering treatment. Women-specific impacts of social media messaging on MOUD engagement is an underexplored and important avenue of research to explore.

Although social media was identified as a site of discrimination, it was simultaneously a venue where women sought and received encouragement for sustained treatment and recovery. Studies have begun to explore ways people use online platforms for opioid-related help seeking [63–65]. Social media and online platforms or forums may have potential to facilitate sustained MOUD engagement. As such, mobile health interventions that leverage these platforms for positive reinforcement and social support may be important community-based complements to clinical treatment protocols. Given increased social isolation, mental health concerns, and substance use risk associated with the COVID-19 pandemic [7] this is a particularly timely avenue to explore. Additionally, health communication efforts that promote “success stories” [29,66] related to long-term treatment engagement could reduce MOUD-related stigma at the community and individual level by normalizing MOUD and promoting positive benefits associated with sustained MOUD engagement.

Women in our study had internalized messaging that MOUD is “substituting one drug for another” or has harmful health impacts. Other studies report how patients perceive methadone to be physically harmful [67–72], despite limited or mixed empirical evidence [73–77]. More research is needed to explore these relationships, and to consider the implication of gender on medication side-effects that impact a woman’s physical appearance (e.g., weight gain and tooth decay). Additionally, better understanding synergistic relationships between MOUD and mental health medications is an important line of future research.

In vocalizing fears, perceptions, and experiences related to MOUD pharmacotherapies, women identified a gap in patient–provider education around expectations of treatment duration, and a need for increased shared decision making in regard to MOUD selection. Women also expressed opioid-specific distrust of providers due to prescribing practices and the opioid crisis, and subsequent perceived unethical relationships between providers and the pharmaceutical industry. People that believe in medical conspiracy theories may be less likely to adhere to recommended treatment protocols [78], and is therefore important to examine. Taken together, these findings point to opportunities for improved patient education that could be incorporated into larger health communication interventions.

The extant literature on women and substance use treatment engagement primarily identifies the importance of connecting women to programs that promote safety external to treatment settings, such as community-based programs for women experiencing intimate partner violence [18]. Our findings on facilitators of treatment engagement suggest the importance of creating a sense of safety within treatment settings. Basic acts of kindness constituted “safety” for women within treatment settings, which is understandable given the vulnerabilities of daily living [18,79] and fractured social relationships experienced...
by women with active OUD [23–25]. Collectively, these findings can guide programmatic interventions and staff trainings to foster a sense of safety within treatment spaces. Lastly, peer workers may be best positioned to address hierarchies within treatment and recovery settings, promote safe treatment environments, and identify relevant women-specific services by offering relatable support [80–82]. Increased funding for peer workers and creating opportunities for women to pursue this certification may provide “hope” for those new to treatment [29].

Taken together, women-identified barriers and facilitators to MOUD engagement elicited in this project hold important potential for MOUD engagement and OUD outcomes among this population. Key implications for future research and interventions at the community and clinical level are summarized below (Table 3). Although some of our findings may apply to both men and women, we posit they are experienced differently and require more investigation.

Table 3. Implications for Research and Intervention.

| Community level                                                                 |
|---------------------------------------------------------------------------------|
| 1. Health communication efforts that promote treatment “success” stories         |
| 2. Mobile health interventions to promote group social support for treatment engagement for women with OUD |
| 3. Outreach and education to address discrimination in workplace and online environments |

| Clinical level                                                                 |
|--------------------------------------------------------------------------------|
| 4. Patient education around the concept of OUD as a chronic condition, the importance of MOUD for treating OUD, and realistic expectations for treatment duration |
| 5. Shared decision making for MOUD selection between patients and providers    |
| 6. Interventions that assess and address social hierarchies within treatment settings |
| 7. Understand MOUD side effects and interactions with mental health pharmacotherapies |
| 8. Integrate peer workers into treatment settings                              |
| 9. Examine and address opioid-specific provider mistrust                       |

4.2. Limitations

Project findings are drawn from a convenience sample of 20 women enrolled in MOUD for at least 90 days. Recruitment was difficult for some group interview sessions, which resulted in occasional “no shows” and smaller groups than planned. Although small, our sample size aligns with norms in qualitative research and provides a depth of data and innovative findings [33,37]. Additionally, research suggests that longer duration of MOUD (e.g., ≥5 years) increases the likelihood of sustained recovery over the subsequent ten years [15]. Because the average length of treatment for our sample was 2.8 years, we did not distinguish factors associated with extended MOUD engagement, highlighting an area for future research.

5. Conclusions

We still know relatively little as to why or how women who do access MOUD remain engaged with it over time. Findings presented throughout this article provide critical context on the experiences of women in MOUD treatment, and are important additions to the substance use literature. Novel barriers to treatment engagement identified by women include community-based discrimination as experienced via social media and in the workplace; internalized stigma among MOUD patients that creates hierarchies within treatment settings; opioid-specific mistrust of providers; and women-specific perceptions of MOUD side effects, synergies, and treatment duration. We close by identifying facilitators to treatment engagement, including the importance of cultivating a sense of safety in treatment settings, the value of integrating peer workers into clinical settings, and the potential benefit of social media and other online platforms. In sum, project findings identify key implications for research and interventions to promote MOUD engagement for women with OUD. As treatment access continues to expand in response to COVID-
era innovations regarding MOUD, addressing project-identified barriers and facilitators collectively at the community and clinical level hold potential for innovative patient-centered care and increased MOUD engagement for women with OUD.

**Author Contributions:** Conceptualization, A.F.-G. and E.A.E.; methodology, A.F.-G. and E.A.E.; software, C.H.; validation, A.F.-G., E.A.E. and C.H.; formal analysis, A.F.-G. and E.A.E.; investigation, A.F.-G., E.A.E. and C.H.; resources, E.A.E.; writing—original draft preparation, A.F.-G.; writing—review and editing, A.G. and E.A.E.; project administration, E.A.E.; funding acquisition, E.A.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** This project was supported by the University of Massachusetts Worcester Center for Clinical and Translational Science (UMCCTS) Grant No. UL1TR001453. Evans is also supported by The Greenwall Foundation, the National Institute on Drug Abuse (NIDA) UG3 DA004830-02S1, and the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT) Grant No. 1H79T1081387-01.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Trinity Health of New England (protocol code MMC-18-17) for studies involving humans.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Appendix A. Participant Demographics and Characteristics Survey**

| About You and Your Household |
|-------------------------------|
| 1. How old are you? ________ years old |

2. Do you consider yourself Hispanic, Latina/o or Chicana/o?
   - [ ] Yes
   - [ ] No

3. Which best describes your race? (check all that apply)
   - [ ] White
   - [ ] Black or African American
   - [ ] Asian or Pacific Islander
   - [ ] American Indian or Alaska Native
   - [ ] Other (please specify):  

4. What is your current marital status? (check one)
   - [ ] Married
   - [ ] In a civil union or domestic partnership
   - [ ] Living with partner or significant other
   - [ ] Divorced or legally dissolved a domestic partnership or separated
   - [ ] Widowed
   - [ ] Never married
   - [ ] Not sure

5. Which of the following do you identify most closely with? (check all that apply)
   - [ ] Lesbian, gay, or homosexual
   - [ ] Straight or heterosexual
   - [ ] Bisexual
   - [ ] Other, please describe:

6. What is your current gender identity?
   - [ ] Female
   - [ ] Male
   - [ ] Gender queer, neither exclusively male nor female
   - [ ] Transgender
   - [ ] Other (please specify):
   - [ ] Decline to answer
7. What is the highest grade or year of school you have ever completed? (check one)

- □ Less than high school or GED
- □ High school graduate or GED
- □ Trade, vocational or tech training after high school
- □ Some college or an Associate’s degree
- □ Bachelor’s degree
- □ Post graduate training or advanced degree

8. What best describes your work status at this time? (check one)

- □ Working full-time
- □ Working part-time
- □ Laid off
- □ Unemployed and looking for work
- □ Unemployed and not looking for work
- □ Disabled and not working
- □ Retired and not working

9. Are you currently a student?

- □ Yes
- □ No

10. Are you a military Veteran?

- □ Yes
- □ No

11. Are you currently pregnant?

- □ Yes
- □ No
- □ Don’t know

12. Do any children under the age of 18 living in your household? (check all that apply)

- □ No, there are no children younger than 18
- □ Yes, there are children younger than age 15 (14 years old or younger)
- □ Yes, there are children who are ages 15 to 17 years old

13. Which of these categories is the best estimate of your total annual household income? (check one)

- □ USD10,000 or less
- □ USD10,001-USD20,000
- □ USD20,001-USD29,999
- □ USD30,000-USD39,999
- □ USD40,000-USD49,999
- □ USD50,000-USD59,999
- □ USD60,000-USD74,999
- □ USD75,000-USD99,999
- □ USD100,000-USD149,999
- □ USD150,000 or more
- □ Over USD150,000

Substance Use

Tell us about your use of each substance. Include use that was prescribed by a medical professional and use that was not prescribed, for example as used illicitly, “on the street,” or “borrowed from a friend/family member.”

| Substance Description | How Old Were You When You First Tried? (If Never, Enter n/a) | For How Many Years Did You Use? (If None, Enter 0) | How Many Days in the Past 30 Days Have You Used? (If None, Enter 0) |
|-----------------------|-------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| 1. Heroin             | ___ years old                                              | ___ years                                       | ___ days                                       |
| 2. Fentanyl           | ___ years old                                              | ___ years                                       | ___ days                                       |
| (Actiq, Duragesic, Fentora, Abstral, Onsolis) |                             |                                                  |                                                  |
| 3. Oxycodone (oxycontin, oxydo, percocet, roxicet) | ___ years old | ___ years | ___ days |
| 4. Methadone          | ___ years old                                              | ___ years                                       | ___ days                                       |
| 5. Any other opiate or analgesic (pain pills) (vicodin, norco, demerol) | ___ years old | ___ years | ___ days |
| 6. Buprenorphine (suboxone, subutex) | ___ years old | ___ years | ___ days |
| 7. Naltrexone (vivitrol) | ___ years old | ___ years | ___ days |
| 8. Alcohol            | ___ years old                                              | ___ years                                       | ___ days                                       |
| 9. Marijuana, cannabis | ___ years old | ___ years | ___ days |
| 10. Cocaine, methamphetamine, amphetamines | ___ years old | ___ years | ___ days |
| 11. Sedatives, hypnotics, tranquilizers (valium, xanax, librium) | ___ years old | ___ years | ___ days |
Appendix B. Interview Guide for Patients

[if patient] Can you tell me about how long you have been in treatment here and your main concerns about your health or social situation right now?

I’d like to tell you about “digital storytelling.” The best way to do that is to show you an example. [play example] Making stories like this can have benefits for the person and for society. Today I want to ask you for your thoughts about using digital storytelling as a way to help women (1) enter and stay in treatment for their opioid problems and (2) become a part of their community.

Appendix B.1. Topic 1: Potential Benefits and Limitations of a DST Intervention

Imagine we are creating a set of digital stories as told by women receiving medications to treat opioid problems. Our goal is to have these women share their stories of resilience. For example, women might be asked to tell stories of how they overcame challenges to enter or stay in treatment. We would want to show these stories to women who have entered treatment recently, to encourage remaining in treatment, and also to women who are not yet in treatment but could benefit from it, to encourage treatment entry.

1. What are your initial thoughts about the pros and cons of having women in treatment for opioid problems share their stories of resilience through “digital storytelling”?
   a. Pros
   b. Cons

Another goal is to use the stories as an opportunity for women being treated for opioid problems to integrate with their community. I define community integration like what you see on the paper in front of you. Let’s go over this together. [go over info and check comprehension]

2. How might these stories be helpful, or not so helpful, for supporting physical integration of women who are_____?
   a. making the story
   b. sharing it with others?

Probe: For example, creating stories might create a space where women learn from each other about the availability of community resources and how and why to access them

3. How about in relation to social integration? How might these stories be helpful, or not so helpful, for supporting social integration of women who are_____?
   a. making the story
   b. sharing it with others?

Probe: For example, creating stories might provide opportunities for women to have interactions with non-substance-using community members, both in-person and online

4. How about in relation to psychological integration? How might these stories be helpful, or not so helpful, for supporting psychological integration of women who are_____?
   a. making the story
   b. sharing it with others?

Probe: For example, by sharing how they entered and stayed in treatment, women might recognize that they themselves are models of resilience, which might give women a new personal identity (e.g., as an “opioid survivor”) and thereby increase women’s self-efficacy for continuing in treatment and also create a sense of belonging in the community.

Women might also receive acceptance and support from community members because of their ability to overcome opioids. Such experiences might help women to feel valued in their community, and thus contribute to social cohesion and enable women to feel more in control of their future.
5. How might it be beneficial, or not, if some of the stories were to highlight connections between treatment with medications for opioid problems and a woman's ability to integrate with the broader community?

6. For which groups of women in treatment with medications for opioid problems might these types of stories of resilience be most helpful?
   a. in what ways and why?

7. For whom might the stories be least helpful, in what ways, and why?

8. How might stories of women's resilience create opportunities for learning by the treatment center staff on how to resolve barriers faced by women in treatment?
   a. How about especially in relation to women's ability to “self-manage” their treatment, and cope with their opioid use disorder as a chronic illness?
   b. How about in relation to women's integration with their community?

Appendix B.2. Topic 2: Perceived Challenges and Ideas on How to Overcome Them

1. What challenges could we expect to have as we create a set of digital stories of resilience as told by women in treatment with medications for opioid problems? What are your ideas on how to overcome those challenges?

2. What challenges could we expect to have as we pilot-test those stories of resilience as an intervention for women who are new to treatment or at risk for dropout? What are your ideas on how to overcome those challenges?

Appendix B.3. Topic 3: Resources Needed to Further Develop and Pilot-Test DST for This Population

1. What things would we need to be able to give voice to the experiences of women being treated with medications for opioid problems?
   a. Staffing, resources, skills, collaborators, buy-in?

2. How about if we wanted to pilot-test the storytelling with women who are new to treatment? What would we need to be able to do that?
   a. Staffing, resources, skills, collaborators, buy-in?

3. In what way might it be possible to integrate storytelling as a health intervention into the existing set of health and social services for women in being treated with medications for opioid problems?
   a. What would be the pros and cons of offering DST as a “stand alone” health intervention?

References

1. U.S. Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health; United States Department of Health and Human Services: Washington, WA, USA, 2016. Available online: https://addiction.surgeongeneral.gov/surgeon-generals-report.pdf (accessed on 1 November 2016).

2. Kosten, T.R.; Petrakis, I.L. The hidden epidemic of opioid overdoses during the coronavirus disease 2019 pandemic. *JAMA Psychiatry* 2021, 78, 585–586. [CrossRef] [PubMed]

3. Marsh, J.C.; Park, K.; Lin, Y.A.; Bersamira, C. Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007–2014. *J. Subst. Abuse. Treat.* 2018, 87, 79–85. [CrossRef] [PubMed]

4. VanHouten, J.P.; Rudd, R.A.; Ballesteros, M.F.; Mack, K.A. Drug overdose deaths among women aged 30–64 years—United States, 1999–2017. *MMWR* 2019, 68, 1–5. [CrossRef] [PubMed]

5. Alexander, G.C.; Stoller, K.B.; Haffajee, R.L.; Saloner, B. An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19. *Ann. Intern. Med.* 2020, 173, 57–58. [CrossRef] [PubMed]

6. Ochalek, T.A.; Cumpston, K.L.; Wills, B.K.; Gal, T.S.; Moeller, F.G. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. *JAMA* 2020, 324, 1673–1674. [CrossRef]

7. Volkow, N.D. Collision of the COVID-19 and addiction epidemics. *Ann. Intern. Med.* 2020, 173, 61–62. [CrossRef]

8. Evans, E.A.; Grella, C.; Upchurch, D. Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. *Soc. Psychiatry Psychiatr. Epidemiol.* 2017, 52, 901–912. [CrossRef]
9. Hser, Y.; Evans, E.; Huang, D.; Weiss, R.; Saxon, A.; Carroll, K.M.; Woody, G.; Liu, D.; Wakim, P.; Matthews, A.G.; et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. *Addiction* 2016, 111, 695–705. [CrossRef]

10. Schulte, M.; Hser, Y.; Saxon, A.; Evans, E.; Li, L.; Huang, D.; Hillhouse, M.; Thomas, C.; Ling, W. Risk factors associated with HCV among opioid-dependent patients in a multisite study. *J. Community Health* 2015, 40, 940–947. [CrossRef]

11. Krebs, E.; Urada, D.; Evans, E.A.; Huang, D.; Hser, Y.L.; Nossy, B. The costs of crime during and after publicly funded treatment for opioid use disorders: A population-level study for the state of California. *Addiction* 2017, 112, 838–851. [CrossRef]

12. Krawczyn, N.; Favole, A.; Yang, J.; Tofighi, B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: A scoping review. *Addict. Sci. Clin. Pract.* 2021, 16, 1–15. [CrossRef]

13. Nunes, E.V.; Levin, F.R.; Reilly, M.P.; El-Bassel, N. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade? *J. Subst. Abus. Treat.* 2021, 122, 108196. [CrossRef]

14. Mauro, P.M.; Gutkind, S.; Annunziato, E.M.; Samples, H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. *JAMA Netw. Open* 2022, 5, e223821. [CrossRef]

15. Hser, Y.I.; Evans, E.A.; Grella, C.; Ling, W.; Anglin, D. Long-term course of opioid addiction. *Harv. Rev. Psychiatry* 2015, 23, 76–89. [CrossRef]

16. Greenfield, S.F.; Brooks, A.J.; Gordon, S.M.; Green, C.A.; Kropp, R.K.; Lincoln, M.; Hien, D.; Miele, G.M. Substance abuse treatment entry, retention, and outcome in women: A review of the literature. *Drug Alcohol Depend.* 2007, 86, 1–21. [CrossRef]

17. Office on Women’s Health. Opioid Use, Misuse, and Overdose in Women. Available online: https://www.womenshealth.gov/files/documents/final-report-opioid-508.pdf (accessed on 1 July 2017).

18. Bailey, K.; Trevillon, K.; Gilchrist, G. What works for whom and why: A narrative systematic review of interventions for reducing post-traumatic stress disorder and problematic substance use among women with experiences of interpersonal violence. *J. Subst. Abus. Treat.* 2019, 99, 88–103. [CrossRef]

19. Evans, E.A.; Goff, S.; Upchurch, D.; Grella, C.E. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. *Addict. Behav.* 2020, 102, 106149. [CrossRef]

20. Campbell, C.I.; Weisner, C.; LeResche, L.; Ray, G.T.; Saunders, K.; Sullivan, M.D.; Banta-Green, C.J.; Merrill, J.O.; Silverberg, M.J.; Boudreau, D.; et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. *Am. J. Public Health* 2010, 100, 2541–2547. [CrossRef]

21. Ashley, O.; Marsden, M.; Brady, T. Effectiveness of substance abuse treatment programming for women: A review. *Am. J. Drug Alcohol Abuse* 2003, 29, 19–53. [CrossRef]

22. Kremer, M.E.; Arora, K.S. Clinical, ethical, and legal considerations in pregnant women with opioid abuse. *Obstet. Gynecol.* 2015, 126, 474–478. [CrossRef]

23. Campbell, N.; Ettorre, E. *Gendering Addiction: The Politics of Drug Treatment in a Neurochemical World*; Palgrave MacMillan: London, UK, 2011.

24. Choi, S.; Adams, S.M.; Morse, S.A.; MacMaster, S. Gender differences in treatment retention among individuals with co-occurring substance abuse and mental health disorders. *Subst. Use Misuse* 2015, 50, 653–663. [CrossRef] [PubMed]

25. Hser, Y.L.; Anglin, M.D.; Booth, M.W. Sex differences in addiction careers. *Am. J. Drug Alcohol Abus.* 1987, 13, 253–280.

26. Elms, N.; Link, K.; Newman, A.; Brogly, S.B.; Kingston Houseof Recovery for Women and Children. Need for women-centered treatment for substance use disorders: Results from focus group discussions. *Harm Reduct. J.* 2018, 15, 40. [CrossRef] [PubMed]

27. Holbrook, A.M. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: Science and stigma. *Am. J. Drug Alcohol Abuse* 2015, 41, 371–373. [CrossRef]

28. Sanders, J. *Women in Narcotics Anonymous: Overcoming Stigma and Shame*; Palgrave MacMillan: New York, NY, USA, 2014.

29. Paterno, M.; Fiddian-Green, A.; Gabrium, A. Moms supporting moms: Digital storytelling with peer mentors in recovery from substance use. *Health Promot. Pract.* 2020, 19, 823–832. [CrossRef]

30. Evans, E.A.; Li, L.; Pierce, J.; Hser, Y.L. Explaining long-term outcomes among drug dependent mothers treated in women-only versus mixed-gender programs. *J. Subst. Abus. Treat.* 2013, 43, 293–301. [CrossRef]

31. Tracy, K.; Wallace, S.P. Benefits of peer support groups in the treatment of addiction. *Subst. Aitus. Rehabil.* 2016, 7, 143. [CrossRef]

32. Meyer, J.P.; Isaccs, K.; El-Shahawy, O.; Burlew, A.K.; Wechsberg, W. Research on women with substance use disorders: Reviewing progress and developing a research and implementation roadmap. *Drug Alcohol Depend.* 2019, 197, 158–163. [CrossRef] [PubMed]

33. Creswell, J.D.; Creswell, J.W. *Research Design: Qualitative, Quantitative, and Mixed Methods Approaches*; SAGE Publications: Thousand Oaks, CA, USA, 2011.

34. Jones, L.; Wells, K. Strategies for academic and clinician engagement in community-participatory partnered research. *Jama* 2007, 297, 407–410. [CrossRef]

35. Fiddian-Green, A.; Kim, S.; Gabrium, A.; Larkey, L.K.; Peterson, J.C. Restor(y)ing health: A conceptual model of the effects of digital storytelling. *Health Promot. Pract.* 2019, 20, 502–512. [CrossRef]

36. Flyvbjerg, B. Five misunderstandings about case-study research. *Qual. Inv.* 2006, 12, 219–245. [CrossRef]

37. Charmaz, K. *Constructing Grounded Theory*; SAGE Publications: Thousand Oaks, CA, USA, 2014.

38. Corbin, J.M.; Strauss, A. *Grounded theory research: Procedures, canons, and evaluative criteria.* *Qual. Soc.* 1990, 13, 3–21. [CrossRef]
39. Lindlof, T.R.; Taylor, B.C. Sensemaking: Qualitative data analysis and interpretation. *Qual. Commun. Res. Methods* **2011**, *3*, 241–281.

40. Gee, J.P. *How to Do Discourse Analysis: A Toolkit*; Routledge Press: London, UK, 2010.

41. Morse, J.; Field, P. *Nursing Research: The Application of Qualitative Approaches*; Nelson Thornes: Cheltenham, UK, 1995.

42. Riessman, C. *Narrative Methods for the Human Sciences*; SAGE Publications: Thousand Oaks, CA, USA, 2008.

43. Denzin, N.; Lincoln, Y. *The landscape of Qualitative Research*; SAGE Publications: Thousand Oaks, CA, USA, 2007.

44. Ulin, P.R.; Robinson, E.T.; Tolley, E.E. *Qualitative Methods in Public Health: A Field Guide for Applied Research*; Wiley: New York, NY, USA, 2005.

45. Adams, S.M.; Peden, A.R.; Hall, L.A.; Rayens, M.K.; Staten, R.R.; Leukefeld, C.G. Predictors of retention of women offenders in a community-based residential substance abuse treatment program. *J. Addict. Nurs.* **2011**, *22*, 103–116. [CrossRef]

46. Evans, E.A.; Kellegher, A.; Li, L.; Min, J.; Huang, D.; Urada, D.; Hser, Y.L.; Nosyk, B. Gender differences in mortality among treated opioid dependent patients. *Drug Alcohol Depend.* **2015**, *155*, 228–235. [CrossRef] [PubMed]

47. Van Boekel, L.C.; Brouwers, E.P.; Van Weeghel, J.; Garretsen, H.F. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. *Drug Alcohol Depend.* **2016**, *155*, 228–235. [CrossRef] [PubMed]

48. Betancourt, J.R.; Brouwers, E.P.; Van Weeghel, J.; Garretsen, H.F. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. *Drug Alcohol Depend.* **2013**, *131*, 23–35. [CrossRef] [PubMed]

49. Betancourt, J.R.; Green, A.R.; Carrillo, M.J.E. Defining cultural competence: A practical framework for addressing racial/ethnic disparities in health and health care. *Public Health Rep.* **2003**, *118*, 293. [CrossRef] [PubMed]

50. Tervalon, M.; Murray-Garcia, J. Cultural humility versus cultural competence: A critical distinction in defining physician training outcomes in multicultural education. *J. Health Care Poor Underserved* **1998**, *9*, 117–125. [CrossRef] [PubMed]

51. Metzl, J.; Hansen, H. Structural competency: Theorizing a new medical engagement with stigma and inequality. *Soc. Sci. Med.* **2014**, *103*, 126–133.

52. Substance Abuse and Mental Health Services Administration. *National Strategy for Suicide Prevention Implementation Assessment Report*; Center for Mental Health Services, Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2017. Available online: https://store.samhsa.gov/system/files/sma17-5051.pdf (accessed on 1 February 2019).

53. Curtis, B.; Bergman, B.; Brown, A.; McDaniel, J.; Harper, K.; Eisenhart, E.; Hufnagel, M.; Heller, A.T.; Ashford, R. Characterizing participation and perceived engagement benefits in an integrated digital behavioral health recovery community for women: A cross-sectional survey. *JMIR Ment. Health* **2019**, *6*, e13352. [CrossRef]

54. D’Agostino, A.R.; Optican, A.R.; Sowles, S.J.; Krauss, M.J.; Escobar Lee, K.; Cavazos-Rehg, P.A. Social networking online to recover from opioid use disorder: A study of community interactions. *Drug Alcohol Depend.* **2017**, *181*, 5–10. [CrossRef]

55. Lee, E.; Cooper, R.J. Codeine addiction and internet forum use and support: Qualitative ethnographic study. *JMIR Ment. Health* **2019**, *6*, e12354. [CrossRef] [PubMed]

56. Grady, K.E.; Jaffe, J.H. Buprenorphine treatment and 12-step meeting attendance: Conflicts, compatibilities, and patient outcomes. *J. Subst. Abus. Treat.* **2015**, *57*, 89–95. [CrossRef]

57. Woo, J.; Bhalerao, A.; Bawor, M.; Bhatt, M.; Dennis, B.; Mouravsva, N.; Zielinski, L.; Samaan, Z. “Don’t judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. *Subst. Abus. Res. Treat.* **2017**, *11*, 1178221816685087. [CrossRef] [PubMed]

58. Van Boekel, L.C.; Brouwers, E.P.; Van Weeghel, J.; Garretsen, H.F. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. *Drug Alcohol Depend.* **2016**, *155*, 228–235. [CrossRef] [PubMed]

59. Campbell, N.D. Using Women: Gender, Drug Policy, and Social Justice; Psychology Press: London, UK, 2000.

60. Tervalon, M.; Murray-Garcia, J. Cultural humility versus cultural competence: A critical distinction in defining physician training. *Int. J. Drug Policy* **2014**, *25*, 407–415. [CrossRef]
68. Muthulingam, D.; Bia, J.; Madden, L.M.; Farnum, S.O.; Barry, D.T.; Altice, F.L. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. *J. Subst. Abus. Treat.* 2019, 100, 18–28. [CrossRef] [PubMed]

69. Notley, C.; Blyth, A.; Maskrey, V.; Pinto, H.; Holland, R. Exploring the concepts of abstinence and recovery through the experiences of long-term opiate substitution clients. *Subst. Abus.* 2015, 36, 232–239. [CrossRef] [PubMed]

70. Rosenblum, A.; Magura, S.; Joseph, H. Ambivalence toward methadone treatment among intravenous drug users. *J. Psychoact. Drugs* 1991, 23, 21–27. [CrossRef] [PubMed]

71. Stancliff, S.; Myers, J.E.; Steiner, S.; Drucker, E. Beliefs about methadone in an inner-city methadone clinic. *J. Urban Health* 2002, 79, 571–578. [CrossRef] [PubMed]

72. Sutker, P.; Allain, A.; Moan, C. Addict attitudes toward methadone maintenance: A preliminary report. *Int. J. Addict.* 1974, 9, 337–343. [CrossRef]

73. Abed, H.; Hassona, Y. Oral healthcare management in heroin and methadone users. *Br. Dent. J.* 2019, 226, 563–567. [CrossRef]

74. Brondani, M.; Park, P.E. Methadone and oral health—A brief review. *Am. Dent. Hyg. Assoc.* 2011, 85, 92–98.

75. Ding, Z.; Chen, Y.; Wang, X.; Zhou, X.; Xu, Y.; Ma, Z.; Jiang, M. A comparison of bone quality and its determinants in young opioid-dependent women with healthy control group. *Drug Alcohol Depend.* 2017, 175, 232–236. [CrossRef]

76. Titsas, A.; Ferguson, M.M. Impact of opioid use on dentistry. *Aust. Dent. J.* 2002, 47, 94–98. [CrossRef]

77. Zador, D.; Wall, P.L.; Webster, I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. *Addiction* 1996, 91, 1053–1061. [CrossRef] [PubMed]

78. Oliver, J.E.; Wood, T. Medical conspiracy theories and health behaviors in the United States. *JAMA Intern. Med.* 2014, 174, 817–818. [CrossRef] [PubMed]

79. El-Bassel, N.; Gilbert, L.; Wu, E.; Go, H.; Hill, J. Relationship between drug abuse and intimate partner violence: A longitudinal study among women receiving methadone. *Am. J. Public Health* 2005, 95, 465–470. [CrossRef] [PubMed]

80. Fallin-Bennett, A.; Elswick, A.; Ashford, K. Peer support specialists and perinatal opioid use disorder: Someone that’s been there, lived it, seen it. *Addict. Behav.* 2020, 102, 106204. [CrossRef] [PubMed]

81. Scott, C.K.; Grela, C.E.; Nicholson, L.; Dennis, M.L. Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users. *J. Subst. Abus. Treat.* 2018, 86, 30–35. [CrossRef]

82. Tracy, K.; Burton, M.; Nich, C.; Rounsaville, B. Utilizing peer mentorship to engage high recidivism substance-abusing patients in treatment. *Am. J. Drug Alcohol Abus.* 2011, 37, 525–531. [CrossRef] [PubMed]